Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

Published:2010-09-30 Issue:3 Volume:117 Page:572-580
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Cortes Jorge,Quintás-Cardama Alfonso,Jones Dan,Ravandi Farhad,Garcia-Manero Guillermo,Verstovsek Srdan,Koller Charles,Hiteshew Jody,Shan Jenny,O'Brien Susan,Kantarjian Hagop

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med.,2006

2. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha;Cortes;Blood.,2003

3. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia;Kantarjian;Blood.,2004

4. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response;Press;Clin Cancer Res.,2007

5. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate;Cortes;Clin Cancer Res.,2005

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review;International Journal of Clinical Pharmacy;2023-12-26

2. The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia;British Journal of Haematology;2022-01-06

3. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?;Frontiers in Immunology;2021-08-17

4. The Interferon-Alpha Revival in CML;Hematologic Malignancies;2021

5. Imatinib: The First-Line CML Therapy;Hematologic Malignancies;2021